FDA says the Zepbound shortage is over. Here's what that means for compounding pharmacies, patients who used off-brand versions
The decision will largely prevent compounding pharmacies from making and selling compounded versions of the drug in the next two to three months.
Hosted on MSN2d
Elon Musk Weighs In on Weight-Loss Drug Stocks. Is LLY or NVO a Better Buy?
Weight-loss drug stocks were catapulted into the spotlight in 2024, creating a lucrative, groundbreaking, and high-stakes ...
Is Eli Lilly Stock a Buy?
Eli Lilly's stock has been a strong winner over the past few years, powered by its portfolio of glucagon-like peptide-1 ...
Sleep Apnea Device Maker Stocks Slide on FDA Ruling for Eli Lilly's Zepbound
Shares of ResMed and Inspire Medical Systems fell after the FDA approved Eli Lilly's weight-loss drug Zepbound to treat ...
2 Pharmaceutical Growth Stocks to Buy Now and Hold for Decades
If you're too busy to keep monitoring your stock portfolio every other day, then investing in stocks that won't cause you a ...
Better Buy: Eli Lilly vs. Novo Nordisk. The Answer Is Becoming Abundantly More Clear.
Eli Lilly and Novo Nordisk are the two biggest names in the pharmaceutical sector, but I see one as the clear-cut winner for ...
NBC Chicago12d
FDA says the Zepbound shortage is over. Here's what that means for compounding pharmacies, patients who used off-brand versions
which allows commercially insured patients without coverage for Zepbound to buy a month's supply for around $650. Under that program, patients whose commercial insurance plan covers Zepbound can ...